[go: up one dir, main page]

WO2002031198A3 - Cancer-linked genes as targets for chemotherapy - Google Patents

Cancer-linked genes as targets for chemotherapy Download PDF

Info

Publication number
WO2002031198A3
WO2002031198A3 PCT/US2001/031607 US0131607W WO0231198A3 WO 2002031198 A3 WO2002031198 A3 WO 2002031198A3 US 0131607 W US0131607 W US 0131607W WO 0231198 A3 WO0231198 A3 WO 0231198A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
disclosed
chemotherapy
targets
linked genes
Prior art date
Application number
PCT/US2001/031607
Other languages
French (fr)
Other versions
WO2002031198A2 (en
Inventor
Paul E Young
Stephen Horrigan
Zoe Weaver
Gregory A Endress
Original Assignee
Avalon Pharmaceuticals
Paul E Young
Stephen Horrigan
Zoe Weaver
Gregory A Endress
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Paul E Young, Stephen Horrigan, Zoe Weaver, Gregory A Endress filed Critical Avalon Pharmaceuticals
Priority to US10/399,225 priority Critical patent/US20040072192A1/en
Priority to EP20010981443 priority patent/EP1399584A2/en
Priority to CA 2425643 priority patent/CA2425643A1/en
Priority to AU2002213084A priority patent/AU2002213084A1/en
Priority to JP2002534562A priority patent/JP2004533206A/en
Publication of WO2002031198A2 publication Critical patent/WO2002031198A2/en
Publication of WO2002031198A3 publication Critical patent/WO2002031198A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of diagnosing and treating cancer using the gene sequences. A novel gene and polypeptide are also disclosed.
PCT/US2001/031607 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy WO2002031198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/399,225 US20040072192A1 (en) 2001-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
EP20010981443 EP1399584A2 (en) 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
CA 2425643 CA2425643A1 (en) 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
AU2002213084A AU2002213084A1 (en) 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
JP2002534562A JP2004533206A (en) 2000-10-11 2001-10-11 Cancer-related genes as targets for chemotherapy

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US23960500P 2000-10-11 2000-10-11
US23929400P 2000-10-11 2000-10-11
US23929700P 2000-10-11 2000-10-11
US60/239,294 2000-10-11
US60/239,605 2000-10-11
US60/239,297 2000-10-11
US23980200P 2000-10-12 2000-10-12
US23980500P 2000-10-12 2000-10-12
US23980600P 2000-10-12 2000-10-12
US60/239,806 2000-10-12
US60/239,805 2000-10-12
US60/239,802 2000-10-12
US24062200P 2000-10-16 2000-10-16
US60/240,622 2000-10-16
US24168200P 2000-10-19 2000-10-19
US24172300P 2000-10-19 2000-10-19
US60/241,723 2000-10-19
US60/241,682 2000-10-19
US24493200P 2000-10-31 2000-10-31
US60/244,932 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002031198A2 WO2002031198A2 (en) 2002-04-18
WO2002031198A3 true WO2002031198A3 (en) 2003-12-31

Family

ID=27581180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031607 WO2002031198A2 (en) 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy

Country Status (5)

Country Link
EP (1) EP1399584A2 (en)
JP (1) JP2004533206A (en)
AU (1) AU2002213084A1 (en)
CA (1) CA2425643A1 (en)
WO (1) WO2002031198A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097408B2 (en) 2004-10-15 2012-01-17 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
ES2369695T3 (en) 2003-02-26 2011-12-05 A & G PHARMACEUTICAL, INC. METHODS TO INCREASE THE PROLIFERATION OF CELLS B.
AU2004261260B2 (en) 2003-08-01 2011-01-27 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
SG177225A1 (en) * 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028193A1 (en) * 1996-01-30 1997-08-07 Melcorp Diagnostics, Inc. Compositions and methods useful in the detection and/or treatment of cancerous conditions
US5855889A (en) * 1995-05-31 1999-01-05 Washington University Mammaglobin, a mammary-specific breast cancer protein
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855889A (en) * 1995-05-31 1999-01-05 Washington University Mammaglobin, a mammary-specific breast cancer protein
WO1997028193A1 (en) * 1996-01-30 1997-08-07 Melcorp Diagnostics, Inc. Compositions and methods useful in the detection and/or treatment of cancerous conditions
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 12 October 1999 (1999-10-12), CRKVENJAKOV R ET AL.: "Human gene expression product cDNA sequence SEQ ID No: 1355", retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AAZ13886 *
DATABASE EMBL [online] EBI; 14 June 2001 (2001-06-14), SCHLEGEL R ET AL: "Human cervical cancer marker nucleic acid 4635", XP002243432, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AAH73361 *
DATABASE EMBL [online] EBI; 16 September 2002 (2002-09-16), SCHLEGEL R ET AL.: "Human prostate expression marker cDNA 24394", XP002243431, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. ABV24403 *
DATABASE EMBL [online] EBI; 2 January 2000 (2000-01-02), ZHANG C. ET AL.: "Homo sapiens PRO2000 mRNA", XP002243375, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AF118088 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097408B2 (en) 2004-10-15 2012-01-17 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Also Published As

Publication number Publication date
AU2002213084A1 (en) 2002-04-22
CA2425643A1 (en) 2002-04-18
WO2002031198A2 (en) 2002-04-18
EP1399584A2 (en) 2004-03-24
JP2004533206A (en) 2004-11-04

Similar Documents

Publication Publication Date Title
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001030964A3 (en) Anti-cancer nucleic acid and protein targets
WO2000050588A3 (en) Genes associated with diseases of the colon
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
AU2154801A (en) Method for linking molecular substances
WO1999067384A3 (en) Prostate cancer-associated genes
WO2005035724A3 (en) Cancer-linked genes as targets for chemotherapy
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2003076579A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097802A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
DE69837397D1 (en) GENETIC CHANGES ASSOCIATED WITH CANCER
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof
WO2003076587A3 (en) Cancer-linked gene as target for chemotherapy
WO2001000799A8 (en) Novel protein and dna thereof
WO2003076571A3 (en) Cancer-linked gene as target for chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002534562

Country of ref document: JP

Ref document number: 2425643

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001981443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10399225

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001981443

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001981443

Country of ref document: EP